Legal provisions of COM(2000)816 - Standards of quality and safety for the collection, testing, processing, storage, and distribution of human blood and blood components - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
dossier | COM(2000)816 - Standards of quality and safety for the collection, testing, processing, storage, and distribution of human blood and blood ... |
---|---|
document | COM(2000)816 |
date | January 27, 2003 |
Contents
- CHAPTER I - GENERAL PROVISIONS
- Article 1 - Objectives
- Article 2 - Scope
- Article 3 - Definitions
- Article 4 - Implementation
- CHAPTER II - OBLIGATIONS ON MEMBER STATES AUTHORITIES
- Article 5 - Designation, authorisation, accreditation or licensing of blood establishments
- Article 6 - Hospital blood banks
- Article 7 - Provisions for existing establishments
- Article 8 - Inspection and control measures
- CHAPTER III - PROVISIONS FOR BLOOD ESTABLISHMENTS
- Article 9 - Responsible person
- Article 10 - Personnel
- CHAPTER IV - QUALITY MANAGEMENT
- Article 11 - Quality system for blood establishments
- Article 12 - Documentation
- Article 13 - Record keeping
- CHAPTER V - HAEMOVIGILANCE
- Article 14 - Traceability
- Article 15 - Notification of serious adverse events and reactions
- CHAPTER VI - PROVISIONS FOR THE QUALITY AND SAFETY OF BLOOD AND BLOOD COMPONENTS
- Article 16 - Provision of information to prospective donors
- Article 17 - Information required from donors
- Article 18 - Eligibility of donors
- Article 19 - Examination of donors
- Article 20 - Voluntary and unpaid blood donation
- Article 21 - Testing of donations
- Article 22 - Storage, transport and distribution conditions
- Article 23 - Quality and safety requirements for blood and blood components
- CHAPTER VII - DATA PROTECTION
- Article 24 - Data protection and confidentiality
- CHAPTER VIII - EXCHANGE OF INFORMATION, REPORTS AND PENALTIES
- Article 25 - Information exchange
- Article 26 - Reports
- Article 27 - Penalties
- CHAPTER IX - COMMITTEES
- Article 28 - Regulatory procedure
- Article 29 - Technical requirements and their adaptation to technical and scientific progress
- Article 30 - Consultation of scientific committee(s)
- CHAPTER X - FINAL PROVISIONS
- Article 31 - Amendment of Directive 2001/83/EC
- Article 32 - Transposition
- Article 33 - Entry into force
- Article 34 - Addressees
CHAPTER I - GENERAL PROVISIONS
Article 1 - Objectives
Article 2 - Scope
2. Where blood and blood components are collected and tested for the sole purpose and exclusive use in autologous transfusion and are clearly identified as such, the requirements to be complied with in respect thereof shall be in accordance with those referred to in Article 29(g).
3. This Directive shall apply without prejudice to Directives 93/42/EEC(15), 95/46/EC or 98/79/EC(16).
4. This Directive does not apply to blood stem cells.
Article 3 - Definitions
(a) 'blood' shall mean whole blood collected from a donor and processed either for transfusion or for further manufacturing;
(b) 'blood component' shall mean a therapeutic constituent of blood (red cells, white cells, platelets, plasma) that can be prepared by various methods;
(c) 'blood product' shall mean any therapeutic product derived from human blood or plasma;
(d) 'autologous transfusion' shall mean transfusion in which the donor and the recipient are the same person and in which pre-deposited blood and blood components are used;
(e) 'blood establishment' shall mean any structure or body that is responsible for any aspect of the collection and testing of human blood or blood components, whatever their intended purpose, and their processing, storage, and distribution when intended for transfusion. This does not include hospital blood banks;
(f) 'hospital blood bank' shall mean a hospital unit which stores and distributes and may perform compatibility tests on blood and blood components exclusively for use within hospital facilities, including hospital based transfusion activities;
(g) 'serious adverse event' shall mean any untoward occurrence associated with the collection, testing, processing, storage and distribution, of blood and blood components that might lead to death or life-threatening, disabling or incapacitating conditions for patients or which results in, or prolongs, hospitalisation or morbidity;
(h) 'serious adverse reaction' shall mean an unintended response in donor or in patient associated with the collection or transfusion of blood or blood components that is fatal, life-threatening, disabling, incapacitating, or which results in, or prolongs, hospitalisation or morbidity;
(i) 'blood component release' shall mean a process which enables a blood component to be released from a quarantine status by the use of systems and procedures to ensure that the finished product meets its release specification;
(j) 'deferral' shall mean suspension of the eligibility of an individual to donate blood or blood components such suspension being either permanent or temporary;
(k) 'distribution' shall mean the act of delivery of blood and blood components to other blood establishments, hospital blood banks and manufacturers of blood and plasma derived products. It does not include the issuing of blood or blood components for transfusion.
(l) 'haemovigilance' shall mean a set of organised surveillance procedures relating to serious adverse or unexpected events or reactions in donors or recipients, and the epidemiological follow-up of donors;
(m) 'inspection' shall mean formal and objective control according to adopted standards to assess compliance with this Directive and other relevant legislation and to identify problems.
Article 4 - Implementation
2. This Directive shall not prevent a Member State from maintaining or introducing in its territory more stringent protective measures which comply with the provisions of the Treaty.
In particular, a Member State may introduce requirements for voluntary and unpaid donations, which include the prohibition or restriction of imports of blood and blood components, to ensure a high level of health protection and to achieve the objective set out in Article 20(1), provided that the conditions of the Treaty are met.
3. In carrying out the activities covered by this Directive the Commission may have recourse to technical and/or administrative assistance to the mutual benefit of the Commission and of the beneficiaries, relating to identification, preparation, management, monitoring, audit and control, as well as to support expenditure.
CHAPTER II - OBLIGATIONS ON MEMBER STATES AUTHORITIES
Article 5 - Designation, authorisation, accreditation or licensing of blood establishments
2. For the purpose of paragraph 1, the blood establishment shall submit the information listed in Annex I to the competent authority.
3. The competent authority, having verified whether the blood establishment complies with the requirements set out in this Directive, shall indicate to the blood establishment which activities it may undertake and which conditions apply.
4. No substantial change in activities shall be undertaken by the blood establishment without prior written approval by the competent authority.
5. The competent authority may suspend or revoke the designation, authorisation, accreditation or licence of a blood establishment if inspection or control measures demonstrate that the blood establishment does not comply with the requirements of this Directive.
Article 6 - Hospital blood banks
Article 7 - Provisions for existing establishments
Article 8 - Inspection and control measures
2. Inspection and control measures shall be organised by the competent authority on a regular basis. The interval between two inspections and control measures shall not exceed two years.
3. Such inspection and control measures shall be carried out by officials representing the competent authority who must be empowered to:
(a) inspect blood establishments as well as facilities of any third parties on its own territory entrusted by the holder of the designation, authorisation, accreditation or licence referred to in Article 5 with the task of carrying out evaluation and testing procedures pursuant to Article 18;
(b) take samples for examination and analysis;
(c) examine any documents relating to the object of the inspection, subject to the provisions in force in the Member States at the time of the entry into force of this Directive and which place restrictions on these powers with regard to the descriptions of the method of preparation.
4. The competent authority shall organise inspection and other control measures as appropriate in the event of any serious adverse event or reaction or suspicion thereof in accordance with Article 15.
CHAPTER III - PROVISIONS FOR BLOOD ESTABLISHMENTS
Article 9 - Responsible person
- ensuring that every unit of blood or blood components has been collected and tested, whatever its intended purpose, and processed, stored, and distributed, when intended for transfusion, in compliance with the laws in force in the Member State,
- providing information to the competent authority in the designation, authorisation, accreditation or licensing procedures as required in Article 5,
- the implementation of the requirements of Articles 10, 11, 12, 13, 14 and 15 in the blood establishment.
2. The responsible person shall fulfil the following minimum conditions of qualification:
(a) he/she shall possess a diploma, certificate or other evidence of formal qualifications in the field of medical or biological sciences awarded on completion of a university course of study or a course recognised as equivalent by the Member State concerned;
(b) he/she shall have practical post-graduate experience in relevant areas for at least two years, in one or more establishments which are authorised to undertake activities related to collection and/or testing of human blood and blood components, or to their preparation, storage, and distribution.
3. The tasks specified in paragraph 1 may be delegated to other persons who shall be qualified by training and experience to perform such tasks.
4. Blood establishments shall notify the competent authority of the name of the responsible person referred to in paragraph 1 and other persons referred to in paragraph 3 together with information on the specific tasks for which they are responsible.
5. Where the responsible person or such other persons referred to in paragraph 3 are permanently or temporarily replaced, the blood establishment shall provide immediately the name of the new responsible person and his or her date of commencement to the competent authority.
Article 10 - Personnel
CHAPTER IV - QUALITY MANAGEMENT
Article 11 - Quality system for blood establishments
2. The Commission shall establish the Community standards and specifications referred to in Article 29(h) for the activities relating to a quality system to be carried out by a blood establishment.
Article 12 - Documentation
2. Member States shall take all necessary measures in order to ensure that access is provided to these documents for officials entrusted with inspection and control measures referred to in Article 8.
Article 13 - Record keeping
2. The competent authority shall keep records of the data received from the blood establishments according to Articles 5, 7, 8, 9 and 15.
CHAPTER V - HAEMOVIGILANCE
Article 14 - Traceability
To this end, Member States shall ensure that blood establishments implement a system for identification of each single blood donation and each single blood unit and components thereof enabling full traceability to the donor as well as to the transfusion and the recipient thereof. The system must unmistakably identify each unique donation and type of blood component. This system shall be established in accordance with the requirements referred to in Article 29(a).
With regard to blood and blood components imported from third countries, Member States shall ensure that the donor identification system to be implemented by blood establishments permits an equivalent level of traceability.
2. Member States shall take all necessary measures in order to ensure that the system used for the labelling of blood and blood components collected, tested, processed, stored, released and/or distributed on their territory complies with the identification system referred to in paragraph 1 and the labelling requirements listed in Annex III.
3. Data needed for full traceability in accordance with this Article shall be kept for at least 30 years.
Article 15 - Notification of serious adverse events and reactions
- any serious adverse events (accidents and errors) related to the collection, testing, processing, storage and distribution of blood and blood components which may have an influence on their quality and safety, as well as any serious adverse reactions observed during or after transfusion which may be attributed to the quality and the safety of blood and blood components are notified to the competent authority,
- blood establishments have in place a procedure accurately, efficiently and verifiably to withdraw from distribution blood or blood components associated with the notification referred to above.
2. These serious adverse events and reactions shall be notified in accordance with the procedure and notification format referred to in Article 29(i).
CHAPTER VI - PROVISIONS FOR THE QUALITY AND SAFETY OF BLOOD AND BLOOD COMPONENTS
Article 16 - Provision of information to prospective donors
Article 17 - Information required from donors
Article 18 - Eligibility of donors
2. The results of the donor evaluation and testing procedures shall be documented and any relevant abnormal findings shall be reported to the donor.
Article 19 - Examination of donors
Article 20 - Voluntary and unpaid blood donation
2. Member States shall submit reports to the Commission on these measures two years after the entry into force of this Directive, and thereafter every three years. On the basis of these reports the Commission shall inform the European Parliament and the Council of any necessary further measure it intends to take at Community level.
Article 21 - Testing of donations
Member States shall ensure that blood and blood components imported into the Community are tested in conformity with requirements listed in Annex IV.
Article 22 - Storage, transport and distribution conditions
Article 23 - Quality and safety requirements for blood and blood components
CHAPTER VII - DATA PROTECTION
Article 24 - Data protection and confidentiality
For that purpose, they shall ensure:
(a) that data security measures are in place as well as safeguards against unauthorised data additions, deletions or modifications to donor files or deferral records, and transfer of information;
(b) that procedures are in place to resolve data discrepancies;
(c) that no unauthorised disclosure of such information occurs, whilst guaranteeing the traceability of donations.
CHAPTER VIII - EXCHANGE OF INFORMATION, REPORTS AND PENALTIES
Article 25 - Information exchange
Article 26 - Reports
2. The Commission shall transmit to the European Parliament, the Council, the Economic and Social Committee and the Committee of the Regions, the reports submitted by the Member States on the experience gained in implementing this Directive.
3. The Commission shall transmit to the European Parliament, the Council, the Economic and Social Committee and the Committee of the Regions, commencing on 1 July 2004 and every three years thereafter, a report on the implementation of the requirements in this Directive, and in particular those relating to inspection and control.
Article 27 - Penalties
CHAPTER IX - COMMITTEES
Article 28 - Regulatory procedure
2. Where reference is made to this paragraph, Articles 5 and 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.
The period referred to in Article 5(6) of Decision 1999/468/EC shall be set at three months.
3. The Committee shall adopt its rules of procedure.
Article 29 - Technical requirements and their adaptation to technical and scientific progress
The following technical requirements and their adaptation to technical and scientific progress shall be decided in accordance with the procedure referred to in Article 28(2):
(a) traceability requirements;
(b) information to be provided to donors;
(c) information to be obtained from donors including the identification, health history, and the signature of the donor;
(d) requirements concerning the suitability of blood and plasma donors and the screening of donated blood including
- permanent deferral criteria and possible exemption thereto
- temporary deferral criteria;
(e) storage, transport and distribution requirements;
(f) quality and safety requirements for blood and blood components;
(g) requirements applicable to autologous transfusions;
(h) Community standards and specifications relating to a quality system for blood establishments;
(i) Community procedure for notifying serious adverse reactions and events and notification format.
Article 30 - Consultation of scientific committee(s)
CHAPTER X - FINAL PROVISIONS
Article 31 - Amendment of Directive 2001/83/EC
"Article 109
For the collection and testing of human blood and human plasma, Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC(17) shall apply."Article 32 - Transposition
When Member States adopt those provisions, they shall contain a reference to this Directive or shall be accompanied by such reference on the occasion of their official publication. Member States shall determine how such reference is to be made.
2. Member States shall communicate to the Commission the texts of the provisions of national law that they have already adopted or which they adopt in the field governed by this Directive.